International Archives of Allergy and Immunology最新文献

{"title":"α2-3 Sialic acids-decorated allergens exert a tolerogenic effect on CD4 T cells from Der p 2 - allergic patients.","authors":"Brigitte-Carole Keumatio Doungtsop, Eleonora Nardini, Evert E Peterse, Hakan Kalay, Serge A Versteeg, Ronald Van Ree, Esther E C de Jong, Yvette Van Kooyk","doi":"10.1159/000543157","DOIUrl":"https://doi.org/10.1159/000543157","url":null,"abstract":"<p><strong>Background: </strong>Allergen-specific immunotherapy (AIT) is so far the only disease-modifying therapy for allergy, resulting in a long-lasting tolerance. However, the existing safety concerns and the need for more efficacious alternatives that shorten the duration of treatment have stimulated research into the development of novel alternatives. Some of these novel alternatives involve modifying allergens with molecules that target innate immunomodulatory receptors to suppress the immune activity of immune cells.</p><p><strong>Method: </strong>Freshly prepared monocyte-derived dendritic cells (moDCs) from mite-allergic and non-atopic volunteers were treated with α2-3 sialic acid-conjugated recombinant Der p 2 ((sia)-Der p 2) and unconjugated Der p 2 in culture and matured with Toll-like receptor (TLR) 1/2 (Pam3CSK4) (Pam3) and 2/4 (lipopolysaccharide) (LPS) agonists, followed by co-culture with autologous CD4+ T cells. Secretion of cytokines in supernatants were measured by ELISA and expression of cell surface and intracellular markers was measured by flow cytometry.</p><p><strong>Results: </strong>Sia-Der p 2 unlike Der p 2, modulated moDCs from mite-allergic volunteers by reducing expression of CD83 and CXCR5. We also observed that sia-Der p 2-treated moDCs in the presence of Pam3 and LPS significantly suppressed the proportion of CD25+, Ki67+, IL-13+ and IFN-y+ CD4+ T cells of mite-allergic volunteers while Der p 2-treated moDCs did not. Sia-Der p 2-treated moDC did not alter these CD4+ T cell populations in non-atopic volunteers.</p><p><strong>Conclusion: </strong>Our data suggests that Der p 2 conjugated with α2-3 sialic acids modifies moDCs and promotes the differentiation of allergen specific CD4+ T cells towards a regulatory profile.</p>","PeriodicalId":13652,"journal":{"name":"International Archives of Allergy and Immunology","volume":" ","pages":"1-19"},"PeriodicalIF":2.5,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142864315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of Fibroblast Growth Factor 2 Impact and Mechanism on Broncho-Pulmonary Dysplasia.","authors":"Ling Lu, Ye-Dan Liu, Dong-Yun Liu, Rong Jin, Zheng-Hai Qu","doi":"10.1159/000543105","DOIUrl":"https://doi.org/10.1159/000543105","url":null,"abstract":"<p><strong>Objective: </strong>Epithelial-mesenchymal transition (EMT) of alveolar epithelial cells is an important mechanism for the onset and development of broncho-pulmonary dysplasia (BPD).The role of FGF-2 in BPD is currently unclear. The aim of our study is to investigate the expression of FGF-2 in lung tissue of BPD mice, to further clarify the effect of FGF-2 on EMT in alveolar epithelial cells and to actively search for possible signaling pathways.</p><p><strong>Methods: </strong>The BPD model was induced by exposure to hyperoxia. Lung tissue samples were collected and Hematoxylin and eosin (HE) staining was used to determine the modelling effect. Quantitative Real-time Polymerase Chain Reaction (QRT-PCR), immunohistochemistry were used to detect FGF-2 expression in BPD mice. To further investigate the effect of FGF-2 supplementation and deficiency on EMT in alveolar epithelial cells, A549 cells were cryopreserved, resuspended, cultured and passaged. Transforming growth factor-β1 (TGFβ1) was used to induce EMT. FGF-2 small interfering RNA fragments were synthesised and screened. Fbroblast growth factor receptor1 (FGFR1) expression was inhibited by BGJ398.  (3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H tetrazolium) (MTS) assay was used to detect the effect of FGF-2 and Infigratinib (BGJ398) on cell proliferation. We used qRT-PCR and Western blot to detect the expression of epithelial cell markers, mesenchymal cell markers and EMT-related signaling pathway proteins.</p><p><strong>Results: </strong>Our results showed that the successful established hyperoxia mice model were characteristic by BPD. Hyperoxia decreased FGF-2 on day 4, upregulated FGF-2 on day 21, which resulted in EMT. In vitro, we found that FGF-2 alone increased the expression of mesenchymal markers, decreased the expression of epithelial markers and activated Phosphatidylinositol 3-kinase/Protein kinase B (PI3K/AKT), Small mother against decapentaplegic (Smad), mitogen-activated protein kinase (P38) and extracellular signal-regulated kinase (ERK) signaling pathways. FGF-2 could not reverse but synergistically promote TGF-β1-induced EMT of alveolar epithelial cells. Silencing FGF-2 increased the expression of epithelial marker E-cadherin, inhibited the PI3K/AKT, Smad, and P38 signaling pathways activated by TGF-β1, but activated ERK signaling. FGF-2 receptor inhibitor BGJ398 reversed TGF-β1-induced EMT, decreased the expression of FGFR1, and inhibited ERK signaling pathway activation.</p><p><strong>Conclusions: </strong>FGF2 was closely associated with EMT in BPD mice. Both high and low levels of FGF2 promoted EMT in A549. The FGF-2 receptor inhibitor BGJ398 reversed TGF-β1-induced EMT in A549 by inhibiting the FGFR1/P-ERK signaling pathway.</p>","PeriodicalId":13652,"journal":{"name":"International Archives of Allergy and Immunology","volume":" ","pages":"1-24"},"PeriodicalIF":2.5,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142853416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Allergen Sensitization in Allergic Skin Diseases in Suzhou, East China: A Retrospective Study from 2021 to 2023.","authors":"Chunjiao Zheng, Jiacheng Dong, Peizhen Li, Yan Li, Miaomiao Wang, Yueqian Zhu, Tingting Wu, Naihui Zhou","doi":"10.1159/000543021","DOIUrl":"https://doi.org/10.1159/000543021","url":null,"abstract":"<p><strong>Introduction: </strong>Allergen distribution varies geographically, and local epidemiological data can guide disease prevention and management. We investigated allergen sensitization among patients with three types of allergic skin disease in Suzhou, East China, from 2021 to 2023.</p><p><strong>Methods: </strong>Serum-specific immunoglobulin-E levels were analyzed from 4,603 patients who visited The First Affiliated Hospital of Soochow University between January 2021 and December 2023. Sensitization prevalence to 20 allergen species was assessed, considering age, sex, year, and disease type.</p><p><strong>Results: </strong>Common aeroallergens included Dermatophagoides farinae, Dermatophagoides pteronyssinus, and house dust, while major food allergens were soybean, egg, and crab. Children exhibited higher sensitization rates, with males more sensitized to D. farinae, D. pteronyssinus, Alternaria, and milk, and females more sensitized to Blattella germanica and egg. Compared with previous years, sensitization rates for soybean and milk decreased in 2023, whereas those for D. farinae and crab increased. Patients with atopic dermatitis had the highest overall sensitization rates.</p><p><strong>Conclusion: </strong>Allergen sensitization patterns in Suzhou varied by age, sex, year, and disease type. Understanding these patterns can help improve the management of allergic skin diseases in this region.</p>","PeriodicalId":13652,"journal":{"name":"International Archives of Allergy and Immunology","volume":" ","pages":"1-20"},"PeriodicalIF":2.5,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142835620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Outcomes After Slow Low-Dose Oral Immunotherapy for Cow's Milk.","authors":"Yoshito Matsuo, Shiro Sugiura, Seiya Masukane, Fumi Tanaka, Atsushi Makino, Katsumasa Kitamura, Teruaki Matsui, Yoshihiro Takasato, Komei Ito","doi":"10.1159/000542796","DOIUrl":"https://doi.org/10.1159/000542796","url":null,"abstract":"<p><strong>Introduction: </strong>We previously reported the result of slow low-dose oral immunotherapy (SLOIT), which is a 1-year severity-stratified low-dose OIT for severe cow's milk allergy (CMA) (threshold dose ≤287 mg of cumulative cow's milk [CM] protein at the entry oral food challenge [OFC]). After completing the SLOIT protocol (exit-OFC to cumulative 287 mg of CM protein), the participants were instructed to gradually increase the amount of CM, roughly doubling the increasing pace, if they could consume it symptom-free for 2-3 months (SLOIT-plus). This study evaluated the long-term outcomes of SLOIT and identified the factors associated with these outcomes.</p><p><strong>Methods: </strong>The subjects were 23 children who completed the SLOIT protocol and proceeded with the SLOIT-plus instructions. The proportion of subjects who were desensitized to the full dose (FD; 200 mL of CM) was evaluated. Additionally, factors associated with FD 3 years after SLOIT (FD group) were analyzed. The allergic symptoms provoked in the OFC were quantified using the total score (TS) of the Anaphylaxis Scoring Aichi (ASCA), and the overall severity was expressed as TS/Pro (TS/cumulative protein dosage).</p><p><strong>Results: </strong>The number of subjects who were desensitized to FD within 12, 24, and 36 months was 0 (0%), 3 (13%), and 8 (35%), respectively. The FD group exhibited a larger decrease in TS/Pro, IgE specific to CM, and casein after the SLOIT protocol.</p><p><strong>Conclusions: </strong>A third of the children with severe CMA were desensitized to FD within 36 months after SLOIT. A better response to the 1-year SLOIT protocol was associated with better long-term outcomes.</p>","PeriodicalId":13652,"journal":{"name":"International Archives of Allergy and Immunology","volume":" ","pages":"1-20"},"PeriodicalIF":2.5,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142812974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of Tumour necrosis factor inhibitors, Interleukin-17 inhibitors, and Janus kinase inhibitors in patients with non-radiographic axial spondyloarthritis: A systematic review and network meta-analysis.","authors":"Dan Li, Xinhui Zhang, Yunfei Tian, Jing Zhang, Xiaojuan Zhao, Menghao Li, Yonghong Zhao, Xiuju Liu","doi":"10.1159/000542744","DOIUrl":"https://doi.org/10.1159/000542744","url":null,"abstract":"<p><strong>Introduction: </strong>To systematically assess the efficacy and safety of tumour necrosis factor inhibitors (TNFi), interleukin-17 inhibitors (IL-17i) and Janus kinase inhibitors (JAKi) in patients with non-radiographic axial spondyloarthritis (nr-axSpA).</p><p><strong>Methods: </strong>A systematic literature search was conducted in Pubmed, Embase, Web of Science and the Cochrane Register of Clinical Trials to find randomized controlled trials (RCTs) in patients with nr-axSpA published until June 2023, by two reviewers independently. Data extraction was carried out by two independent investigators. Stata 17.0 software and Review Manager 5.3 software were used to perform the data analysis. The results for binary and continuous variables were expressed as the values of odds ratio (OR) and mean difference (MD) and their 95% confidence interval (CI), respectively.</p><p><strong>Results: </strong>A total of 10 RCTs involving 2,418 participants were included in the analysis. The efficacy rankings were: certolizumab pegol (CZP) 200 mg every 2 weeks (Q2W) > CZP 400 mg every 4 weeks (Q4W) > golimumab (GOL) > bimekizumab (BKZ) > adalimumab (ADA) > upadacitinib (UPA) > etanercept (ETN) > brodalumab (BRO) > ixekizumab (IXE) > secukinumab (SEC) 150 mg no loading (NL) > SEC 150 mg loading dose(LD) > placebo (PBO) for Assessment of SpondyloArthritis international Society response criteria for 40% improvement (ASAS40); GOL > CZP 400 mg Q4W> BKZ > ADA > UPA > CZP 200 mg Q2W > ETN > BRO > SEC 150 mg NL > SEC 150 mg LD > PBO for Assessment of SpondyloArthritis international Society response criteria for 20% improvement (ASAS20). Except for BRO, all treatments resulted in a significant improvement in ASAS40 compared with PBO. In terms of safety, the ranking was: GOL > ADA > PBO > UPA > SEC 150 mg NL > BKZ > IXE > SEC 150 mg LD > ETN > CZP 200 mg Q2W for adverse events (AE). There was no statistical difference in serious adverse events (SAE) among all drugs compared to PBO.</p><p><strong>Conclusions: </strong>Most TNFi could be more effective than JAKi and IL-17i. The safety of the therapies is generally good. However, the efficacy and safety of TNFi/IL-17i/JAKi remains to be further analyzed in studies with larger sample size and longer follow-up times.</p><p><strong>Trial registration: </strong>This study has been registered in the International Prospective Register of Systematic Reviews (PROSPERO), with a registration number of CRD42023423725.</p>","PeriodicalId":13652,"journal":{"name":"International Archives of Allergy and Immunology","volume":" ","pages":"1-26"},"PeriodicalIF":2.5,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142806994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Double-blind, placebo-controlled trial of the efficacy and safety of azelastine hydrochloride in children with perennial allergic rhinitis.","authors":"Jean Bousquet, Ludger Klimek, Hans-Christian Kuhl, Duc Tung Nguyen, Rajesh Kumar Ramalingam, G Walter Canonica, William Berger","doi":"10.1159/000542054","DOIUrl":"https://doi.org/10.1159/000542054","url":null,"abstract":"<p><strong>Background: </strong>Allergic rhinitis (AR) affects up to 40% of the pediatric population. The US practice parameter recommends the use of INAH or INCS as first-line therapy for the treatment of AR. Although not directly targeted to children, the recent US Practice Parameters proposed intranasal antihistamines as first-line therapy whereas the ARIA guidelines did not.</p><p><strong>Methods: </strong>This was a randomized, double-blind, parallel-group study with a duration of 28 days. It compared Azelastine hydrochloride 0.10% and 0.15% to placebo of one spray per nostril twice daily in pediatric subjects with moderate-to-severe symptomatic perennial allergic rhinitis (PAR).</p><p><strong>Results: </strong>A total of 486 subjects were included in the study. The change from baseline rTNSS was statistically significant for 0.15% AZE (P = .005) and 0.10% AZE (P = .015) vs. placebo. 0.15% AZE showed an LS mean change of -3.45 (20.2%) over the 28-day treatment period from a baseline value of 16.60 in rTNSS. 0.10% AZE showed an LS mean change of -3.37 (20.5%) over the 28-day treatment period from a baseline value of 16.35 in rTNSS. Somnolence was reported by one patient in the 0.1% group and one placebo patient (both of mild severity and unlikely to be related to treatment). None of the patients reported fatigue.</p><p><strong>Conclusions: </strong>0.15% AZE significantly improved the overall rTNSS compared with placebo over the 28-day study period. 0.15% AZE was well tolerated in this study.</p>","PeriodicalId":13652,"journal":{"name":"International Archives of Allergy and Immunology","volume":" ","pages":"1-15"},"PeriodicalIF":2.5,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biologics Use for Psoriasis during Pregnancy and Its Related Adverse Outcomes in Pregnant Women and Newborns: Findings from WHO Pharmacovigilance Study.","authors":"Yi Deun Jeong, Hyesu Jo, Hanseul Cho, Wonwoo Jang, Jaeyu Park, Sooji Lee, Hayeon Lee, Kyeongmin Lee, Jiyeon Oh, Xuerong Wen, Lee Smith, Dong Keon Yon","doi":"10.1159/000542217","DOIUrl":"https://doi.org/10.1159/000542217","url":null,"abstract":"<p><strong>Introduction: </strong>The safety of biologics, other than TNF-α inhibitors, during pregnancy has not been sufficiently established. To assess the risk of pregnancy-related adverse outcomes of biologics used for psoriasis, compared to TNF-α inhibitors, we utilized the WHO global pharmacovigilance database (1968-2024).</p><p><strong>Methods: </strong>We utilized the World Health Organization's global pharmacovigilance database from 1968 to 2024. From over 140 million reports from more than 170 countries, we extracted 6,518 reports of pregnancy-related adverse outcomes associated with the biologics of interest. These biologics included TNF-α inhibitors (e.g., etanercept, infliximab, adalimumab, certolizumab pegol), IL-12/IL-23 inhibitor (e.g., ustekinumab), IL-17 inhibitors (e.g., secukinumab, brodalumab, ixekizumab, bimekizumab), and IL-23 inhibitors (e.g., guselkumab, tildrakizumab, risankizumab). Each biologic was compared to TNF-α inhibitors and certolizumab pegol in two separate disproportionality analyses. The reporting odds ratio (ROR) was calculated for maternal, fetal, and neonatal outcomes, categorized into seven major groups. Multivariable and sensitivity analyses were conducted to validate the primary results.</p><p><strong>Results: </strong>The disproportionality analysis showed that, compared to TNF-α inhibitors, most biologics had a lower frequency of pregnancy-related adverse outcomes, with the exception of brodalumab. Specifically, ROR and 95% confidence intervals (CIs) were as follows: ustekinumab (ROR, 0.27; 95% CI: 0.21-0.35), secukinumab (0.17; 0.13-0.22), brodalumab (0.20; 0.02-2.21), ixekizumab (0.05; 0.03-0.08), bimekizumab (0.10; 0.01-0.71), guselkumab (0.09; 0.05-0.15), tildrakizumab (0.02; 0.00-0.14), and risankizumab (0.38; 0.25-0.58). However, risankizumab was reported with a higher frequency of abortion and stillbirth (1.87; 1.32-2.63). These findings were consistent when compared to certolizumab pegol, as well as in multivariable and sensitivity analyses. Furthermore, when comparing other TNF-α inhibitors to certolizumab pegol, infliximab showed a lower frequency of pregnancy-related adverse outcomes (ROR, 0.71; 95% CI: 0.55-0.92), etanercept showed a comparable frequency (1.00; 0.77-1.31), and adalimumab showed a higher frequency (1.42; 1.11-1.81).</p><p><strong>Conclusions: </strong>Biologics used for psoriasis, with the exception of brodalumab, exhibit a lower frequency of pregnancy-related adverse outcomes compared to TNF-α inhibitors and certolizumab pegol, suggesting their potential to be safe options during pregnancy. However, further studies are necessary to evaluate the safety of these biologics during pregnancy, accounting for confounding factors.</p>","PeriodicalId":13652,"journal":{"name":"International Archives of Allergy and Immunology","volume":" ","pages":"1-15"},"PeriodicalIF":2.5,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142768443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk Factors for Severe Allergic Rhinitis and the Association with Serum sIgE Levels: A Study in Guangzhou, China.","authors":"Feng-Wen Shan, Min Zhou, Xin-Yi Zheng, Tong Wu, Ya-Na Zhang, Shuo Wu, Zhao-Hui Shi, Xin Luo, Gui-Xian Liang, He Zhang, He-Xiao Jiang, Ning Kang, Yu-Lian Chen, Qi-Lin Zhou, Guo-Wei Xiong, Jing Su, Yun Cheng, Xue-Kun Huang, Guang-Hui Dong, Qin-Tai Yang","doi":"10.1159/000542863","DOIUrl":"https://doi.org/10.1159/000542863","url":null,"abstract":"<p><strong>Background: </strong>The control of risk factors is crucial for the management of allergic rhinitis (AR), and it contributes to reduce both direct medical costs and indirect economic burdens. The research on risk factors for severe AR and the association between serum allergen-specific immunoglobulin E (sIgE) and the severity of AR is currently limited and inconsistent.</p><p><strong>Methods: </strong>The study utilized data from a cross-sectional epidemiological survey conducted in Guangzhou, China, from April 2023 to March 2024, involved 638 AR patients. We used Visual Analogue Scale (VAS) scores to assess the severity of AR. Data of daily risk factors were collected through face-to-face questionnaires, and serum sIgE levels were measured using the AllergyScreen assay (Mediwiss-Analytic GmbH, Moers, Germany). A generalized linear model was used to investigate the associations.</p><p><strong>Results: </strong>Our findings indicate that patients with severe AR exhibited more unhealthy lifestyle habits and lived in high-risk environments compared to non-severe patients. Physical activity more than three times per week was associated with a reduced risk of severe symptoms (OR: 0.55, 95% CI: 0.36, 0.82). Frequent indoor cleaning also lowered the risk of severe AR (OR: 0.70, 95% CI: 0.56, 0.87). Additionally, a one-level increase in serum sIgE was linked to higher odds of severe AR (OR: 1.26, 95% CI: 1.11, 1.43) after adjusting for risk factors.</p><p><strong>Conclusion: </strong>Severe AR is associated with poor household cleaning and less exercise. Higher serum sIgE levels correspond to a higher risk of severe AR.</p>","PeriodicalId":13652,"journal":{"name":"International Archives of Allergy and Immunology","volume":" ","pages":"1-18"},"PeriodicalIF":2.5,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142768575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global estimates of vaccine-associated hepatic autoimmune disorders and their related vaccines, 1968-2024: An international analysis of the WHO pharmacovigilance database.","authors":"Jinyoung Jeong, Hyesu Jo, Jaeyu Park, Lee Smith, Masoud Rahmati, Kwanjoo Lee, Yeonjung Ha, Dong Keon Yon","doi":"10.1159/000542865","DOIUrl":"https://doi.org/10.1159/000542865","url":null,"abstract":"<p><p>Previous studies have suggested an association between vaccines and autoimmune diseases, but they were limited by their narrow focus and timeframe. Therefore, this study conducted the first large-scale international analysis to investigate the impact of various vaccines on autoimmune liver diseases. Utilizing WHO's VigiBase data from 1968 to 2024, the study identified 1,083 (0.012%) cases of vaccine-associated hepatic autoimmune disorders out of 8,562,584 reported vaccine adverse events. The vaccines with the highest risk of hepatic autoimmune disorders were the hepatitis B vaccine (reporting odds ratio [ROR], 3.52; 95% CI, 2.50-4.95), COVID-19 mRNA vaccines (ROR, 2.95; 95% CI, 2.73-3.18), and papillomavirus vaccines (ROR, 2.13; 95% CI, 1.45-3.13). Additionally, when vaccine-associated hepatic autoimmune disorders occurred, hepato-biliary adverse events were frequently observed to occur concurrently. This study suggests that vaccines may induce hepatic autoimmune disorders and highlights the need for enhanced monitoring before and after vaccination. Additionally, it proposes implementing pre-vaccination screening protocols and post-vaccination monitoring to address this concern.</p>","PeriodicalId":13652,"journal":{"name":"International Archives of Allergy and Immunology","volume":" ","pages":"1-15"},"PeriodicalIF":2.5,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142768464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Osteopontin as a Novel Biomarker in Distinguishing Chronic Rhinosinusitis with Nasal Polyp Endotypes and Predicting Disease Severity.","authors":"Peiqiang Liu, Meng Liu, Yibin Sun, Mengcheng Yu, Weiwei Lei, Yu Xu","doi":"10.1159/000542347","DOIUrl":"https://doi.org/10.1159/000542347","url":null,"abstract":"<p><strong>Introduction: </strong>The objective of this study was to ascertain the predictive value of osteopontin (OPN), a cytokine with pro-inflammatory properties implicated in inflammatory and allergic conditions, in nasal secretions for the identification of chronic rhinosinusitis with nasal polyp (CRSwNP) endotypes and the assessment of disease severity.</p><p><strong>Methods: </strong>A cohort comprising 81 individuals diagnosed with CRSwNP was enrolled, which included 37 subjects with the non-eosinophilic CRSwNP and 44 subjects with the eosinophilic CRSwNP (eCRSwNP), alongside 32 healthy controls (HCs). Nasal secretions and tissue samples were collected from all participants. The quantification of OPN in these samples was conducted using ELISA and immunohistochemistry. Nasal fractional exhaled nitric oxide levels were determined with the Nano Coulomb Breath Analyzer. The diagnostic efficacy of OPN levels in distinguishing eCRSwNP was assessed using the receiver operating characteristic (ROC) curve, while Pearson correlation analysis was employed to evaluate the correlation between OPN levels and disease severity indicators.</p><p><strong>Results: </strong>Concentrations of OPN in nasal secretions were found to be elevated in CRSwNP patients compared to the HC group and significantly higher in patients with eCRSwNP. A positive correlation was identified between OPN levels in nasal secretions and peripheral blood eosinophil counts and percentages, and tissue eosinophil counts, as well as the Visual Analog Scale (VAS) score, Lund-Mackay score, and Lund-Kennedy score. The ROC analysis demonstrated that the OPN level in nasal secretions possesses a robust discriminatory capacity for eCRSwNP, with a cutoff value of 121.05 ng/mL. Furthermore, the OPN concentration was determined to be a more precise predictor of the VAS score, Lund-Mackay score, and Lund-Kennedy score than the CRSwNP endotypes.</p><p><strong>Conclusion: </strong>The findings of this study indicate that OPN is differentially expressed in the nasal secretions of eCRSwNP patients and correlates with eosinophilic inflammation. The presence of OPN in nasal secretions emerges as a novel and potentially valuable biomarker for the differentiation of CRSwNP endotypes and the prognostication of disease severity.</p>","PeriodicalId":13652,"journal":{"name":"International Archives of Allergy and Immunology","volume":" ","pages":"1-11"},"PeriodicalIF":2.5,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142768477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}